Nutra Pharma Corp.
NPHC
$0.00
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 09/30/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 247.80K | 247.80K | 157.90K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 247.80K | 247.80K | 157.90K |
| Cost of Revenue | -- | -- | 181.30K | 181.30K | 149.80K |
| Gross Profit | -- | -- | 66.60K | 66.60K | 8.00K |
| SG&A Expenses | -- | -- | 1.45M | 1.45M | 1.67M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | 1.63M | 1.63M | 1.82M |
| Operating Income | -- | -- | -1.38M | -1.38M | -1.66M |
| Income Before Tax | -- | -- | 7.11M | 7.11M | 21.97M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | 7.11 | 7.11 | 21.97 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | 7.11M | 7.11M | 21.97M |
| EBIT | -- | -- | -1.38M | -1.38M | -1.66M |
| EBITDA | -- | -- | -1.36M | -1.36M | -1.64M |
| EPS Basic | -- | -- | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | -- | -- | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -- | -- | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | -- | -- | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | -- | -- | 29.74B | 29.74B | 29.43B |
| Average Diluted Shares Outstanding | -- | -- | 44.89B | 44.89B | 41.96B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |